Fractyl Health (GUTS) FCF Margin (2023 - 2024)
Fractyl Health (GUTS) reported FCF Margin of 575566.67% for Q4 2024, down 42315238.0% year-on-year from N/an in Q1 2024, and down 341.48% quarter-over-quarter from 130371.43% in Q3 2024.
Fractyl Health (GUTS) has 2 years of FCF Margin data on file, last reported at 575566.67% in Q4 2024.
- For the quarter ending Q4 2024, FCF Margin fell 42315238.0% year-over-year to 575566.67%; the trailing twelve-month figure through Dec 2024 stood at 72350.54% (down 3658887.0% YoY), and the FY2024 full-year result was 72350.54%, down 3658887.0% from the prior year.
- FCF Margin for Q4 2024 stood at 575566.67%, down from 130371.43% in the prior quarter.
- Across five years, FCF Margin topped out at 16265.28% in Q2 2023 and bottomed at 575566.67% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 43.35% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 23.53% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 4.17% |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -575,566.67% |
| Sep 30, 2024 | -130,371.43% |
| Jun 30, 2024 | -46,595.35% |
| Mar 31, 2024 | -35,548.48% |
| Dec 31, 2023 | -152,414.29% |
| Sep 30, 2023 | -30,455.56% |
| Jun 30, 2023 | -16,265.28% |
| Mar 31, 2023 | -191,400.00% |